{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:43:49Z","timestamp":1782603829116,"version":"3.54.5"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ando.2023.03.014","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T03:21:02Z","timestamp":1679541662000},"page":"339-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pituitary and adrenal disorders induced by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"84","author":[{"given":"Fr\u00e9d\u00e9rique","family":"Albarel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Castinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2023.03.014_bib0340","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ando.2023.03.014_bib0345","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J immunol"},{"key":"10.1016\/j.ando.2023.03.014_bib0350","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ando.2023.03.014_bib0355","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u00a0\u2013\u00a0immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0360","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2023.03.014_bib0365","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2023.03.014_bib0370","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2023.03.014_bib0375","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMra1703481","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.014_bib0380","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2023.03.014_bib0385","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.ando.2023.03.014_bib0390","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0395","doi-asserted-by":"crossref","first-page":"101635","DOI":"10.1016\/j.beem.2022.101635","article-title":"Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy","volume":"36","author":"Atkinson","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.014_bib0400","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.014_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0410","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","article-title":"Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma","volume":"19","author":"Feng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2023.03.014_bib0415","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.014_bib0420","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2023.03.014_bib0425","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0430","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2023.03.014_bib0435","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.014_bib0440","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2023.03.014_bib0445","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.014_bib0450","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ando.2023.03.014_bib0455","doi-asserted-by":"crossref","first-page":"836859","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patternsof loss of pituitary function","volume":"12","author":"Jessel1","year":"2022","journal-title":"Front oncol"},{"key":"10.1016\/j.ando.2023.03.014_bib0460","doi-asserted-by":"crossref","first-page":"847917","DOI":"10.3389\/fonc.2022.847917","article-title":"Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression-free and overall survival","volume":"12","author":"Paschou","year":"2022","journal-title":"Front oncol"},{"key":"10.1016\/j.ando.2023.03.014_bib0465","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"24","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2023.03.014_bib0470","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysisi and secondar adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ando.2023.03.014_bib0475","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J Investig Med"},{"key":"10.1016\/j.ando.2023.03.014_bib0480","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ando.2023.03.014_bib0485","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","article-title":"Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma","volume":"166","author":"Quirk","year":"2015","journal-title":"Transl Res"},{"key":"10.1016\/j.ando.2023.03.014_bib0490","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/1744666X.2021.1974297","article-title":"Recent insights into the pathogenesis of autoimmune hypophysitis","volume":"17","author":"Frasca","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ando.2023.03.014_bib0495","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11102-016-0736-z","article-title":"Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects","volume":"19","author":"Bellastella","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2023.03.014_bib0500","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2023.03.014_bib0505","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2023.03.014_bib0510","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.autrev.2008.04.016","article-title":"Pituitary autoimmunity: 30\u00a0years later","volume":"7","author":"Caturegli","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ando.2023.03.014_bib0515","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2023.03.014_bib0520","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.014_bib0525","article-title":"Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies","volume":"2018","author":"Gunawan","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.ando.2023.03.014_bib0530","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/imt-2020-0334","article-title":"Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report","volume":"13","author":"Yu","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ando.2023.03.014_bib0535","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/etm.2022.11709","article-title":"Diabetes insipidus: a rare endocrine complication of immune check point inhibitors: a case report and literature review","volume":"25","author":"Angelousi","year":"2022","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ando.2023.03.014_bib0540","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11102-018-0866-6","article-title":"Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis","volume":"21","author":"De Sousa","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2023.03.014_bib0545","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2023.03.014_bib0550","first-page":"570293","article-title":"Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review","volume":"2015","author":"Majchel","year":"2015","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0555","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2023.03.014_bib0560","article-title":"Clinical heterogeneity of hypophysitis secondary to PD-1\/PD-L1 blockade: insights from four cases","volume":"2019","author":"Lupi","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.ando.2023.03.014_bib0565","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ando.2023.03.014_bib0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ando.2017.12.001","article-title":"SFE\/SFEDP adrenal insufficiency French consensus: introduction and handbook","volume":"79","author":"Reznik","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.014_bib0575","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.014_bib0580","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0033-1355337","article-title":"Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy","volume":"121","author":"Lammert","year":"2013","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.ando.2023.03.014_bib0585","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.014_bib0590","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society For Endocrinology Endocrine Emergency Guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ando.2023.03.014_bib0595","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ando.2023.03.014_bib0600","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side effects of new anticancer therapies: overall monitoring and conclusions","volume":"79","author":"Castinetti","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.014_bib0605","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0610","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ando.2018.07.008","article-title":"Expert opinion on pituitary complications in immunotherapy","volume":"79","author":"Briet","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.014_bib0615","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1530\/EJE-12-1057","article-title":"Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency","volume":"169","author":"Hahner","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0620","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ando.2017.10.009","article-title":"Modalities and frequency of monitoring of patients with adrenal insufficiency. Patient education","volume":"78","author":"Guignat","year":"2017","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.014_bib0625","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ando.2018.03.002","article-title":"Therapeutic patient education in adrenal insufficiency","volume":"79","author":"Guignat","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.014_bib0630","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1530\/EJE-20-0652","article-title":"Evaluation of an individualized education program in pituitary diseases: a pilot study","volume":"183","author":"Albarel","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0635","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison's disease: a rare, persistent and potentially lethal side effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2023.03.014_bib0640","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ando.2018.07.002","article-title":"Expert opinions on adrenal complications in immunotherapy","volume":"79","author":"Haissaguerre","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.014_bib0645","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/cancers15010246","article-title":"Management of endocrine and metabolic toxicities of immune-checkpoint inhibitors: from clinical studies to a real-life scenario","volume":"15","author":"Spagnolo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2023.03.014_bib0650","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eprac.2020.09.016","article-title":"Immune checkpoint inhibitor induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management","volume":"27","author":"Shi","year":"2021","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2023.03.014_bib0655","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2023.03.014_bib0660","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2023.03.014_bib0665","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2023.03.014_bib0670","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:54:55Z","timestamp":1757717695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426623000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003426623000641"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.014","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pituitary and adrenal disorders induced by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}